Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMI580M)

Drug Name

4-Chloro-5,7-diphenyl-7H-pyrrolo[2,3-d]pyrimidine Drug Info

Synonyms

4-Chloro-5,7-diphenyl-7H-pyrrolo[2,3-d]pyrimidine; 4-chloro-5,7-diphenylpyrrolo[2,3-d]pyrimidine; 287177-10-0; CHEMBL426229; AC1M1GSW; MolPort-000-510-379; ZINC2455203; BDBM50088916; SBB039474; BBL001718; STL115578; AKOS000267629; MCULE-6403159172; ST45174715; H6707; L-3752

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 2049536
TTD Drug ID: DMI580M

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Proto-oncogene c-Src (SRC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[2]
Bosutinib	DMTI8YE	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[2]
SKI-758	DMQ8E9R	Ischemia	8B10-8B11	Approved	[3]
Herbimycin A	DM6YWBF	Solid tumour/cancer	2A00-2F9Z	Approved	[4]
AL3818	DM3WP0N	Alveolar soft part sarcoma	2A60-2C35	Phase 3	[5]
CP-868596	DMZIM37	Gastrointestinal cancer	2C11	Phase 3	[5]
Masitinib	DMRSNEU	Amyotrophic lateral sclerosis	8B60.0	Phase 3	[6]
KX-01	DMF0NA9	Actinic keratosis	EK90.0	Phase 3	[7]
Saracatinib	DMBLHGP	Hematologic tumour	2B33.Y	Phase 2	[8]
TPX-0046	DMIVE67	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Proto-oncogene c-Src (SRC)	TT6PKBN	SRC_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Substituted 5,7-diphenyl-pyrrolo[2,3d]pyrimidines: potent inhibitors of the tyrosine kinase c-Src. Bioorg Med Chem Lett. 2000 May 1;10(9):945-9.
2	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
3	Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
4	In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ABL-transfected cells. Leuk Res. 1994 Nov;18(11):867-73.
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8	Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45.
9	Clinical pipeline report, company report or official report of Turning Point Therapeutics.